Angiosarcoma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Angiosarcoma is a rare and aggressive malignant neoplasm originating from vascular or lymphatic endothelial cells, accounting for approximately 1-2% of all soft tissue sarcomas and fewer than 200 cases per year in the United States. Despite this low incidence, angiosarcoma is responsible for a disproportionate share of sarcoma mortality because of its propensity for early systemic dissemination, multifocality, and resistance to many systemic chemotherapy regimens. Primary anatomical sites include the skin (most common — particularly the scalp and face in elderly individuals), the breast (frequently radiation-induced after prior breast cancer radiotherapy), the liver (associated with chemical carcinogens), bone, spleen, and heart (primary cardiac angiosarcoma is exceedingly rare). Angiosarcoma arising in the field of prior radiation therapy — radiation-induced angiosarcoma (RIAS) — represents an increasingly recognized complication of modern cancer treatment, with RIAS of the breast/chest wall appearing 5-15 years after breast cancer radiotherapy. Cutaneous scalp angiosarcoma predominantly affects elderly men and carries a poor prognosis with 5-year survival below 20% due to early multifocality and high rates of local recurrence and distant metastasis. Overall 5-year survival for all angiosarcoma is approximately 20-35%, varying substantially by primary site and stage. The ANGIOTAX trial established weekly paclitaxel as the reference first-line systemic therapy for metastatic cutaneous angiosarcoma (ORR approximately 45-60%).

Unlike most soft tissue sarcomas, angiosarcoma has identifiable environmental and iatrogenic risk factors in a significant proportion of cases, though the majority remain sporadic with no identifiable etiology. Established causes: chronic lymphedema — Stewart-Treves syndrome describes cutaneous angiosarcoma (lymphangiosarcoma) arising in chronically edematous tissue, classically in the ipsilateral arm of women who underwent radical mastectomy with axillary lymph node dissection for breast cancer; lymphedema creates conditions of impaired immune surveillance and vascular hyperplasia permissive for malignant transformation, developing 5-15 years after surgery; modern sentinel lymph node biopsy has substantially reduced this complication. Radiation-induced angiosarcoma (RIAS): prior ionizing radiation therapy (cumulative dose above 40-50 Gy) is a recognized causative agent with a latency of 5-20 years — most commonly arising as post-breast irradiation angiosarcoma in the chest wall skin and breast parenchyma; increasing in frequency with the expanding population of breast cancer survivors who received adjuvant radiotherapy; characterized by multifocality and MYC proto-oncogene amplification (nearly 100% of RIAS, versus rare in benign atypical vascular lesions, making MYC a diagnostic discriminator by FISH or NGS). Chemical carcinogens associated with hepatic angiosarcoma: vinyl chloride monomer (PVC industry — historical occupational exposure), thorotrast (thorium dioxide contrast agent used before 1950s — 25-30 year latency), inorganic arsenic, and anabolic androgenic steroids. Hereditary hemorrhagic telangiectasia (HHT, ACVRL1/ENG mutations): predisposes to hepatic arteriovenous malformations and may increase hepatic angiosarcoma risk. Immunosuppression (organ transplant, HIV) may contribute to risk in occasional cases. The vast majority of sporadic angiosarcomas harbor KDR (VEGFR2) mutations and PIK3CA alterations as key driver events.

Clinical presentation varies substantially by primary tumor site. Cutaneous angiosarcoma (scalp/face, the most common presentation in elderly men): starts as an innocuous-appearing purple-red, bruise-like, or plaque-like lesion on the scalp that bleeds easily with minor trauma and rapidly spreads multifocally across the scalp and face; lesions are often mistaken for hematomas, eczema, or cellulitis — leading to diagnostic delays of weeks to months; satellite nodules and thickened erythematous plaques develop over weeks; bilateral involvement and extension beyond the scalp to the face, neck, and parotid region occurs. Radiation-induced breast/chest wall angiosarcoma: red, purple, or brown skin plaques or nodules developing in the previously irradiated breast skin or chest wall, often multifocal, arising 5-15 years after radiotherapy; may resemble a new bruise, infection, or inflammatory condition initially. Hepatic angiosarcoma: right upper quadrant abdominal pain (most common), hepatomegaly, rapidly progressive jaundice, and abdominal distension from ascites; spontaneous hepatic rupture with intraperitoneal hemorrhage and hemodynamic instability — a life-threatening emergency — occurs in approximately 15-25% of hepatic angiosarcoma patients. Constitutional features are prominent: fever (often low-grade), fatigue, and dramatic unintentional weight loss. Consumptive coagulopathy (Kasabach-Merritt syndrome) — thrombocytopenia, microangiopathic hemolytic anemia, and disseminated intravascular coagulation (DIC) — may complicate large angiosarcomas. Cardiac angiosarcoma: progressive right-sided heart failure, pericardial effusion with tamponade, arrhythmias, and syncope.

Tissue biopsy is mandatory for definitive diagnosis — the macroscopic and dermoscopic appearances can mimic benign vascular lesions, hematomas, and cellulitis. Punch biopsy (for cutaneous lesions) or CT-guided core needle biopsy (for hepatic/retroperitoneal lesions) provides adequate tissue for histological and immunohistochemical evaluation. Histopathology: infiltrating anastomosing vascular channels lined by atypical endothelial cells with hyperchromatic pleomorphic nuclei; mitotic figures; hemorrhage and necrosis — poorly differentiated high-grade tumors may show solid epithelioid growth patterns. Immunohistochemistry (IHC) confirms endothelial lineage: CD31 (most sensitive endothelial marker, present in >90% of angiosarcoma); CD34; ERG (nuclear marker of endothelial cells — most specific); FLI-1; factor VIII-related antigen (less sensitive). MYC amplification (FISH or NGS): detected in nearly 100% of radiation-induced and post-lymphedema angiosarcoma — essential diagnostic discriminator from benign atypical vascular lesions. Negative for epithelial markers (CK, EMA) and melanoma markers (S100, MelanA). MRI: superior for local soft tissue delineation — heterogeneous T1/T2 signal, avid gadolinium enhancement reflecting vascularity; critical for surgical planning. CT chest-abdomen-pelvis: staging for pulmonary metastases (most common distant site), liver, and lymph node involvement. PET-CT: highly FDG-avid; evaluates extent and multifocality. Molecular profiling by NGS: KDR (VEGFR2) mutations, PIK3CA mutations, and CDKN2A loss are characteristic; also evaluates TMB and MSI for immunotherapy eligibility.

Localized angiosarcoma: wide surgical excision with negative margins (R0) is the primary curative intent approach — however, achieving clear margins in cutaneous scalp angiosarcoma is technically challenging given the multifocal growth pattern and frequent subclinical satellite spread beyond visible lesion borders. In cutaneous scalp angiosarcoma, re-resection rates are high (often over 50%) due to positive margins; adjuvant radiotherapy (IMRT or proton therapy, 60-66 Gy) significantly reduces local recurrence risk and is standard after resection. Neoadjuvant chemotherapy (paclitaxel) may be used to achieve downsizing before surgery in locally advanced cutaneous angiosarcoma. For radiation-induced breast/chest wall angiosarcoma: wide re-excision of the involved skin and underlying tissue; post-mastectomy skin excision may be required for multifocal RIAS; reconstruction after adequate margins confirmed. Systemic therapy for advanced or metastatic angiosarcoma: weekly paclitaxel (80 mg/m2 IV on days 1, 8, 15 of a 28-day cycle) — established as the preferred first-line regimen for metastatic cutaneous and RIAS based on the ANGIOTAX Phase II trial (ORR approximately 45%, disease control rate approximately 74%); doxorubicin (75 mg/m2 every 3 weeks) or doxorubicin plus ifosfamide for non-cutaneous (visceral, hepatic, cardiac) angiosarcoma — aligning with standard soft tissue sarcoma first-line treatment. Anti-VEGF therapies: pazopanib 800 mg once daily (approved for second-line soft tissue sarcoma), sorafenib, bevacizumab — demonstrate partial responses in angiosarcoma, typically as second-line options or in combination. Pembrolizumab: responses documented in angiosarcoma regardless of TMB/MSI status (Phase 2 SARC028 cohort), making immunotherapy an emerging option. Propranolol (beta-blocker, 80-120 mg/day orally) has shown anti-angiogenic and anti-proliferative activity in cutaneous angiosarcoma in pilot studies — may be considered as add-on therapy. Hepatic angiosarcoma: generally poor surgical candidate; arterial embolization for hemorrhage control as palliation.

Angiosarcoma carries an overall poor prognosis, with 5-year overall survival of approximately 20-35% across all primary sites — substantially worse than most other soft tissue sarcomas. Prognosis varies markedly by primary site: cutaneous angiosarcoma of the scalp and face has 5-year survival of approximately 10-35% due to multifocal infiltrative growth, high local recurrence rates, and frequent early distant metastasis; radiation-induced angiosarcoma of the breast and chest wall carries 5-year survival of approximately 15-20%; hepatic angiosarcoma has the worst prognosis with median survival of approximately 6 months from diagnosis. Stage I localized cutaneous angiosarcoma at non-scalp sites has significantly better outcomes — approximately 40-55% 5-year survival with complete R0 resection and adjuvant radiotherapy. R0 resection is the strongest predictor of better outcome — patients achieving negative surgical margins have significantly improved survival versus those with residual disease. Adverse prognostic factors include tumor size above 5 cm, deep location, high histological grade, multifocal tumors, prior radiation-induced origin, and the presence of metastases at diagnosis. For metastatic angiosarcoma, weekly paclitaxel achieves objective responses in approximately 45-60% of patients with cutaneous or radiation-induced disease, with median progression-free survival of approximately 4-7 months; overall median survival for metastatic disease is approximately 8-12 months with systemic therapy. Pulmonary metastases develop in approximately 50% of cutaneous angiosarcoma patients despite multimodal local treatment. Late effects requiring monitoring include wound complications, lymphedema, and cardiotoxicity from anthracycline-based regimens. Management at specialist multidisciplinary sarcoma centers significantly improves access to optimal treatment and clinical trial enrollment.

Prevention of radiation-induced angiosarcoma involves using the lowest effective radiotherapy dose and modern techniques (IMRT, proton therapy) that minimize the dose to surrounding normal tissues, though this cannot eliminate the risk entirely given radiotherapy's inherent mutagenic potential. Breast cancer survivors who received chest wall radiation should be educated about the risk of radiation-induced angiosarcoma and encouraged to report any new skin changes — bruise-like lesions, new skin nodules, or skin discolouration — in the radiation field promptly. Prevention of Stewart-Treves syndrome: modern sentinel lymph node biopsy techniques, rather than extensive axillary lymph node dissection, dramatically reduce post-mastectomy lymphedema and thereby reduce angiosarcoma risk. Management of chronic lymphedema with compression and physical therapy may reduce risk.

Any breast cancer survivor who notices a new skin lesion — particularly a bruise-like, purple, or red patch in the previously irradiated chest wall area — should seek medical evaluation within days, not weeks, as radiation-induced angiosarcoma can progress rapidly. Women with post-mastectomy lymphedema who develop new skin changes in the oedematous arm (particularly purplish-red nodules or plaques) require urgent dermatological or surgical oncology review to exclude Stewart-Treves syndrome. New scalp lesions in elderly individuals — particularly rapidly growing, bleeding, or bruise-like plaques — should be biopsied without delay. Any patient with unexplained hepatomegaly, right upper quadrant pain, or sudden intra-abdominal bleeding requires imaging to exclude hepatic angiosarcoma. Early diagnosis substantially improves surgical resectability.